Disclosed are substituted compounds of 4-fluoro-5-(2-fluoropyridin-3-yl)-1-((pyrindin-2-yl)sulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine (Formula I), salts thereof and methods for their preparation. Specific examples of compounds of Formula I include: 1-{ 4-Fluoro-5-(2-fluoropyridin-3-yl)-1-[(4-methylpyridin-2-yl)sulfonyl]-1H-pyrrol-3-yl} -N-methylmethanamine, and 1-{ 4-Fluoro-5-(2-fluoropyridin-3-yl)-1-[(4-methoxypyridin-2-yl)sulfonyl]-1H-pyrrol-3-yl} -N-methylmethanamine. The pyrrolyl compounds have an acid secretion suppressive activity and are potassium-competitive acid blockers. The compounds are useful for treating peptic ulcer, Zollinger-Ellison syndrome, gastritis, reflux esophagitis, symptomatic gastroesophageal reflux disease, Barrett's oesophagus, functional dyspepsia, gastric cancer, stomach MALT lymphoma, or ulcer caused by non-steroidal anti-inflammatory drug, gastric hyperacidity or ulcer due to postoperative stress； or an inhibitor of upper gastrointestinal bleeding due to peptic ulcer, acute stress ulcer, hemorrhagic gastritis or invasive stress
